AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Interest-Expense" stands at 1.57 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 12/31/2023.
AstraZeneca PLC's third quarter result of 0.349 Billion USD for the item "Interest Expense" represents a decrease of -22.57 percent compared to it's second quarter result.
Also, AstraZeneca PLC's third quarter result of 0.349 Billion USD for the item "Interest Expense" represents a decrease of -25.82 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 1.57 Billion USD for the item "Interest Expense" represents a decrease of -7.19 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -11.79 percent compared to the value the year prior.
The 1 year change in percent is -11.79.
The 3 year change in percent is 22.00.
The 5 year change in percent is 18.35.
The 10 year change in percent is 50.29.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Interest Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Interest Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Interest Expense | 317,433,206,677.55 |
![]() | Novartis AG - Interest Expense | 255,096,620,580.91 |